| During admission | At discharge | ||||
---|---|---|---|---|---|---|
No stroke | Stroke | P value | No stroke | Stroke | P value | |
(n = 7,874) | (n = 56) | (n = 78744) | (n = 56) | |||
Coronary angiography | 32.6% | 12.5%* | 0.002 | Â | Â | Â |
Percutaneous coronary intervention | 14.5% | 5.4% | 0.08 | Â | Â | Â |
Elective | 10.2% | 1.8% | 0.42 | Â | Â | Â |
Urgent/Emergency PCI (UA/NSTEMI) | 4.2% | 3.6% | Â | Â | Â | Â |
Aspirin | 98% | 91% | 0.001 | 93% | 57% | 0.001 |
β blockers | 75% | 46% | 0.001 | 80% | 38% | 0.001 |
Clopidogrel | 76% | 55% | 0.001 | 68% | 38% | 0.001 |
ACE inhibitors | 25.6% | 33.9% | 0.16 | 72% | 47% | 0.001 |
Angiotensin receptor blockers | 4.7% | 1.8% | 0.30 | 6.8% | 1.8% | 0.1 |
HMG-CoA reductase inhibitor | 95% | 89% | 0.06 | 92% | 58% | 0.001 |
GPIIb/IIa inhibitors | 7.8% | 3.6% | 0.25 | Â | Â | Â |
Thrombolytic therapy | Â | Â | Â | Â | Â | Â |
t-PA | 3% | 13% | 0.09 | Â | Â | Â |
Streoptkinase | 42% | 40% | Â | Â | Â | Â |
Reteplase | 44% | 47% | Â | Â | Â | Â |
Tenektopase | 11% | 0% | Â | Â | Â | Â |
Unfractionated heparin | 49.5% | 33.9% | 0.02 | Â | Â | Â |
LMWH (enoxaparin) | 39.1% | 21.4% | 0.02 | Â | Â | Â |